Insulet Corp
XMUN:GOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Insulet Corp
XMUN:GOV
|
US |
Intrinsic Value
The intrinsic value of 
Insulet Corp (GOV) under the Base Case is 260.62 EUR per share.
Compared with the current market price of 136.1 EUR, the stock appears
Undervalued by 48% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Insulet Does
Insulet makes wearable insulin delivery systems for people with diabetes. Its main product is the Omnipod line, a small tubeless pump that sticks to the body and automatically delivers insulin without the need for repeated injections. The company also provides the disposable pods, the controller or app that manages dosing, and training and support for patients and healthcare providers.
- Headquarters
- United States of America US
- Employees
- 5 400
- IPO date
- May 15, 2007
Insulet has a narrow economic moat
Patents make Omnipod’s insulin-delivery technology harder to copy, while changing pumps requires patients to learn a different system and review treatment settings with their care team. Together, these barriers help Insulet retain customers without making competing pumps impossible to develop or adopt.
Read the full moat analysis
Revenue & Expenses Breakdown
Insulet Corp
Earnings Waterfall
Insulet Corp
The intrinsic value for Insulet Corp (GOV) under the Base Case is 260.62 EUR.
Compared with the current market price of 136.1 EUR, the stock appears Undervalued by 48% .